DEBx Medical B.V., a leader in advanced wound care based in Amsterdam, has secured a second round of capital investment led by TVM Capital Healthcare.
This funding will accelerate the company's global expansion efforts, particularly in the management of chronic wounds. The investment comes after a successful first financing round, highlighting the growing confidence in DEBx Medical's innovative solutions, including its flagship product, DEBRICHEM ®.
Chronic wounds impose a significant burden on healthcare systems worldwide, and DEBRICHEM ® has already proven effective in treating thousands of patients. With CE and ISO certifications, DEBx Medical is well-positioned to transform chronic wound management and improve patient outcomes.
The recent investment will support DEBx Medical's strategic expansion into key markets, with a focus on the MENA region. The company is committed to ongoing research and development to introduce new solutions for wound care, prioritizing clinical data and evidence-based medicine.
The investment from TVM Capital Healthcare aligns with DEBx Medical's broader strategy of improving access to quality healthcare solutions in emerging markets. The company's mission is to enhance the lives of patients with chronic wounds and contribute to better healthcare outcomes globally.